Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 21185230)

1.

Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Carbon M, Correll CU.

Dialogues Clin Neurosci. 2014 Dec;16(4):505-24.

3.

Eating disorders in schizophrenia: implications for research and management.

Kouidrat Y, Amad A, Lalau JD, Loas G.

Schizophr Res Treatment. 2014;2014:791573. doi: 10.1155/2014/791573. Epub 2014 Nov 18. Review.

4.

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.

Lian J, Huang XF, Pai N, Deng C.

PLoS One. 2014 Aug 1;9(8):e104160. doi: 10.1371/journal.pone.0104160. eCollection 2014.

5.

Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders.

Miron IC, Baroană VC, Popescu F, Ionică F.

Curr Health Sci J. 2014 Jan;40(1):12-7. doi: 10.12865/CHSJ.40.01.02. Epub 2013 Dec 29. Review.

6.
7.

Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Kishi T, Matsuda Y, Iwata N.

PLoS One. 2014 Feb 4;9(2):e88049. doi: 10.1371/journal.pone.0088049. eCollection 2014.

8.

Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

Bly MJ, Taylor SF, Dalack G, Pop-Busui R, Burghardt KJ, Evans SJ, McInnis MI, Grove TB, Brook RD, Zöllner SK, Ellingrod VL.

Bipolar Disord. 2014 May;16(3):277-88. doi: 10.1111/bdi.12160. Epub 2013 Dec 13.

9.

Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.

Vassas TJ, Burghardt KJ, Ellingrod VL.

Pharmacogenomics. 2014 Jan;15(1):61-7. doi: 10.2217/pgs.13.157.

10.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

11.

Perspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: a qualitative study.

Gault I, Gallagher A, Chambers M.

Patient Prefer Adherence. 2013 Aug 9;7:787-99. doi: 10.2147/PPA.S44894. eCollection 2013.

12.

Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.

Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA.

Child Adolesc Psychiatry Ment Health. 2013 Aug 15;7(1):31. doi: 10.1186/1753-2000-7-31.

13.

Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

Morgan D, Kondabolu K, Kuipers A, Sakhuja R, Robertson KL, Rowland NE, Booth RG.

Neuropharmacology. 2013 Sep;72:274-81. doi: 10.1016/j.neuropharm.2013.04.051. Epub 2013 May 9.

14.

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.

Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G; Adipogenic and Metabolic Effects of APDs Conference Speakers, Allison DB.

Front Psychiatry. 2012 Jun 28;3:62. doi: 10.3389/fpsyt.2012.00062. eCollection 2012.

15.

Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study.

Zhang JP, Weiss JJ, McCardle M, Klopchin H, Rosendahl E, Maayan L, Convit A, Kane JM, Manu P, Correll CU.

J Clin Psychopharmacol. 2012 Aug;32(4):458-64. doi: 10.1097/JCP.0b013e31825cccd2.

16.

Safety and tolerability of antipsychotic polypharmacy.

Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU.

Expert Opin Drug Saf. 2012 Jul;11(4):527-42. doi: 10.1517/14740338.2012.683523. Epub 2012 May 8.

17.

The field of schizophrenia: strengths, weaknesses, opportunities, and threats.

Kane JM, Cornblatt B, Correll CU, Goldberg T, Lencz T, Malhotra AK, Robinson D, Szeszko P.

Schizophr Bull. 2012 Jan;38(1):1-4. doi: 10.1093/schbul/sbr131. Epub 2011 Nov 18. No abstract available.

18.

Etiologies of obesity in children: nature and nurture.

Skelton JA, Irby MB, Grzywacz JG, Miller G.

Pediatr Clin North Am. 2011 Dec;58(6):1333-54, ix. doi: 10.1016/j.pcl.2011.09.006. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk